
    
      Twenty subjects suffering from bipolar disorders treated with specific medications will give
      their informed concent and will included in the study. All will receive in an open study only
      one intravenously dose of Digoxin antibodies (Fab). Their response to this therapy will be
      measured accordingly.Previous medications will be not changed A base line serum Endogenous
      Digitalis-like Compounds (DLC)levels will be measured using a specific laboratory technique
      and these compounds will be measured at 6 and 24 hours after Fab therapy.

      Patients also will be followed using clinical and psychological tests
    
  